Cambrian Bio ATX-304 Shows Positive Phase 1b Metabolic Data
Cambrian Bio's AMPK network activator ATX-304 produced statistically significant reductions in liver fat, visceral adipose tissue, and triglycerides in adults with obesity and prediabetes in a Phase 1b trial presented at the ADA 86th Scientific Sessions. Resting metabolic rate and adiponectin also improved.